查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1471058

抗藥性金黃色葡萄球菌治療市場：按藥物類型、給藥途徑和銷售管道分類 - 全球預測 2024-2030

Methicillin-Resistant Staphylococcus Aureus Drugs Market by Agent Type (Ceftaroline, Daptomycin, Linezolid), Route of Administration (Oral, Parenteral), Sales Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

抗藥性金黃色葡萄球菌治療市場規模預計到2023年為20.9億美元，2024年達到22.1億美元，2030年達到32.2億美元，預計複合年成長率為6.39%。

抗藥性金黃色葡萄球菌（MRSA）藥物是指用於治療金黃色葡萄球菌引起的感染疾病的一類特殊抗生素。對 MRSA 藥物的需求源於 MRSA感染疾病數量的不斷增加，特別是在醫院和療養院等醫療機構。推動 MRSA 藥物需求的關鍵因素包括醫院感染數量的增加、更容易受到此類感染疾病的老年人口的增加以及促進 MRSA 診斷和治療的醫療基礎設施的進步。然而，由於這些藥物的廣泛使用和有時的不當使用而出現抗生素抗藥性是一個重大挑戰。隨著時間的推移，細菌可以進化以抵抗抗生素的作用，使感染疾病難以治療並導致「超級細菌」的出現。此外，旨在發現新抗生素和替代治療方法（包括噬菌體療法、疫苗和創新抗菌材料）的研發工作預計將擴大針對 MRSA 的武器庫。此外，人們對預防措施的興趣日益濃厚，以及能夠及時、準確治療的快速診斷測試的開發，預計將進一步促進 MRSA 藥物市場的成長。

主要市場統計
基準年[2023] 20.9億美元
預測年份 [2024] 22.1億美元
預測年份 [2030] 32.2億美元
複合年成長率（%） 6.39%

Daptomycin類藥物可有效治療 MRSA，越來越多被採用

頭孢洛林是一種稱為頭孢菌素的抗生素，是有效對抗 MRSA 的新一代抗生素。這種抗生素抑制細胞壁的合成，對細菌的生存很重要。它有效地針對許多細菌，包括抗甲氧西林細菌，使其成為治療 MRSA感染疾病的寶貴選擇。Daptomycin是一種胜肽抗生素，可與細菌細胞膜相互作用。其機轉獨特，造成細胞膜電位快速去極化，導致蛋白質、DNA和RNA合成受到抑制，造成細菌死亡。Daptomycin對革蘭氏陽性菌（包括 MRSA）特異性有效，用於治療皮膚和感染疾病。Linezolid是一種屬於Oxazolidinone的抗生素，特別適用於治療 MRSA感染疾病。它的作用是抑制細菌核醣體，阻止生長和複製所需的必需蛋白質的合成。這種作用對某些革蘭氏陽性細菌有效，包括對其他抗生素抗藥性的菌株。Linezolid可用於治療多種感染疾病，包括皮膚感染疾病和MRSA引起的肺炎。

特拉萬星被歸類為醣肽抗生素，透過抑制細菌細胞壁合成和破壞細胞膜電位發揮作用。這兩種作用使其能夠有效治療複雜的皮膚和軟組織感染疾病，包括 MRSA。它具有與萬古黴素相似的作用機制，但對某些抗藥性細菌具有增強的活性。萬古黴素是用於治療 MRSA感染疾病的最古老和最著名的抗生素之一。它屬於胜肽類，透過抑制細菌細胞壁合成來發揮作用。萬古黴素是治療嚴重MRSA感染疾病（包括血流感染、肺炎和心內膜炎）的重要選擇。萬古黴素通常僅在其他抗生素因抗藥性問題而無效或不合適時使用。

由於易於存取銷售管道，對線上管道的偏好正在增加

診斷為或疑似感染疾病MRSA 的患者通常直接從醫院藥局取得藥物。由於在可能危及生命的情況下需要立即給藥，因此優選該管道。醫院備有這些重症加護抗生素的庫存並可快速提供。此外，對於門診病人和慢性 MRSA感染疾病患者，零售藥局可以作為取得處方 MRSA 藥物的主要來源。零售藥局對患者和看護者來說很方便。

線上管道提供無與倫比的便利，輕鬆重新訂購和宅配。這對於行動不便的患者或居住在偏遠地區的患者尤其有利。一些製造商已開始直接透過其網站提供 MRSA 治療。該管道特別有利於長期處方患者，提供便利並可能節省成本。此外，隨著電子商務的興起，網路藥局也成為主導通路。線上藥局迎合了那些尋求便捷獲取、比較購物和宅配選項的精通技術的消費者。

區域洞察

美洲地區因其先進的醫療基礎設施和對 MRSA 感染的高度認知而成為 MRSA 治療的重要市場。這些地區的消費者需求集中在有效、快速的抗生素和副作用較少的治療方法。北美客戶喜歡經過可靠臨床試驗證明療效的藥物。開發新抗生素和治療方法的研究投資是巨大的，包括政府和私營部門為對抗抗生素抗藥性所採取的舉措。美國和加拿大最近的專利反映了 MRSA 治療方案的持續創新，重點是更安全、更有效的抗生素。歐盟 (EU) 國家擁有多元化的 MRSA 治療市場，並高度重視控制 MRSA 爆發的公共衛生舉措和抗生素管理計畫。對 MRSA 藥物的需求是針對與這些管理計劃相容的治療方法，重點是新穎的作用機制和低抗藥性。歐盟國家的投資強勁，公共和私營部門資助新抗生素的研究。中東和非洲地區MRSA藥物市場開拓程度不同，阿拉伯聯合大公國、沙烏地阿拉伯等國家擁有較先進的醫療體系。在這兩個地區，不斷增加的抗生素抗藥性正在推動對有效 MRSA 治療的需求。這些地區的努力包括改善醫療基礎設施、公眾意識提升宣傳活動以及投資研究針對當地 MRSA 菌株基因特徵的治療方法。中國、日本和印度是亞太地區的主要市場，各自的消費者需求和購買行為各不相同。中國和印度的耐甲氧西林金黃色葡萄球菌（MRSA）感染激增凸顯了對負擔得起且易於獲得的治療選擇的需求。兩國都專注於加強抗生素研發能力，中國大力投資開發新藥，印度則加大學名藥，包括抗甲氧西林金黃色葡萄球菌(MRSA)抗生素。

FPNV定位矩陣

FPNV 定位矩陣對於評估抗藥性金黃色葡萄球菌治療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對抗藥性金黃色葡萄球菌治療市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.抗藥性金黃色葡萄球菌治療市場的市場規模與預測是多少？

2.在抗藥性金黃色葡萄球菌治療市場的預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？

3.抗藥性金黃色葡萄球菌治療市場的技術趨勢和法規結構是什麼？

4.抗藥性金黃色葡萄球菌治療市場主要供應商的市場佔有率是多少？

5. 進入抗藥性金黃色葡萄球菌治療市場的適當型態和策略性手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 抗藥性金黃色葡萄球菌引起的感染疾病盛行率增加
      • 私營和公共部門增加對醫療保健的投資
    • 抑制因素
      • 抗藥性金黃色葡萄球菌治療配方中使用的原料的變動成本
    • 機會
      • 持續研發新開發的抗藥性金黃色葡萄球菌治療藥物
      • 抗藥性金黃色葡萄球菌治療藥物專利到期數量增加
    • 任務
      • 耗時且嚴格的監管核准流程
  • 市場區隔分析
    • 藥物類型：Daptomycin有效治療MRSA的進展
    • 銷售管道：由於易於訪問，對線上管道的偏好正在增加
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章抗藥性金黃色葡萄球菌治療藥品市場依藥品分類

  • 頭孢洛林
  • Daptomycin
  • Linezolid
  • 特拉萬辛
  • 萬古黴素

第7章抗藥性金黃色葡萄球菌治療市場：途徑

  • 口服
  • 胃腸外的

第8章抗藥性金黃色葡萄球菌治療藥物市場：依銷售管道

  • 離線
  • 線上

第9章：美洲抗藥性金黃色葡萄球菌治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區抗藥性金黃色葡萄球菌治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章：抗藥性金黃色葡萄球菌治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 英國政府策略投資全球抗菌藥物抗藥性監測，加強亞洲和非洲的衛生系統
    • 瓦西利亞申請 FDA核准新抗生素頭孢比普羅對抗 MRSA
    • BARDA 為 Melinta Therapeutics 提供策略性資助舉措，以改善兒童抗生素的獲取
  • 戰略分析和建議

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-0363DFE0369A

[188 Pages Report] The Methicillin-Resistant Staphylococcus Aureus Drugs Market size was estimated at USD 2.09 billion in 2023 and expected to reach USD 2.21 billion in 2024, at a CAGR 6.39% to reach USD 3.22 billion by 2030.

Methicillin-resistant Staphylococcus Aureus (MRSA) drugs refer to a specialized category of antibiotics that are used to treat infections caused by a type of bacteria known as Staphylococcus aureus, which has become resistant to many of the antibiotics traditionally used to treat bacterial infections, including methicillin. The necessity for MRSA drugs arises from the increasing prevalence of MRSA infections, particularly in healthcare settings such as hospitals and nursing homes, where infections can be severe and spread quickly. Key factors driving the need for their use include the rising number of hospital-acquired infections, the growing elderly population who are more susceptible to such infections, and the advancement of healthcare infrastructure that facilitates better diagnosis and treatment of MRSA. However, the emergence of antibiotic resistance due to widespread and sometimes inappropriate use of these drugs poses a significant challenge. Over time, bacteria can evolve to resist the effects of antibiotics, making infections harder to treat and leading to the development of "superbugs." Furthermore, the ongoing research and development aimed at discovering new antibiotics and alternative treatments, such as bacteriophage therapy, vaccines, and innovative antibacterial materials, promise to broaden the arsenal against MRSA. Additionally, the increasing focus on preventive measures and the development of rapid diagnostic tests to enable timely and precise treatment are expected to contribute further to the growth of the MRSA drugs market.

KEY MARKET STATISTICS
Base Year [2023] USD 2.09 billion
Estimated Year [2024] USD 2.21 billion
Forecast Year [2030] USD 3.22 billion
CAGR (%) 6.39%

Agent Type: Evolving adoption of daptomycin for effective treatment of MRSA

Ceftaroline is part of a class of antibiotics known as cephalosporins and represents a newer generation that is effective against MRSA. This antibiotic disrupts the bacterial cell wall synthesis, which is crucial for the bacteria's survival. It effectively targets many bacteria, including methicillin-resistant ones, making it a valuable option for treating MRSA infections. Daptomycin is a lipopeptide antibiotic, which means it interacts with the bacterial cell membranes. Its mechanism is unique; it causes rapid depolarization of the cell membrane potential, leading to inhibition of protein, DNA, and RNA synthesis, resulting in bacterial death. Daptomycin is specifically effective against gram-positive bacteria, including MRSA, and is used for skin and bloodstream infections. Linezolid belongs to the oxazolidinone class of antibiotics and is especially useful in treating MRSA infections. It operates by interfering with the bacterial ribosome, preventing the synthesis of essential proteins needed for growth and replication. This action is effective against several gram-positive bacteria, including strains resistant to other antibiotics. Linezolid can be used for various infections, including skin infections and pneumonia caused by MRSA.

Telavancin is classified as a lipoglycopeptide antibiotic, which works by inhibiting the synthesis of the bacterial cell wall and disrupting the cell membrane's electrical potential. This dual action makes it a potent option for treating complicated skin and soft tissue infections, including those caused by MRSA. It has a similar mode of action to vancomycin but with enhanced activity against certain resistant bacteria. Vancomycin is one of the oldest and most well-known antibiotics used to treat MRSA infections. It belongs to the glycopeptide class, functioning by inhibiting bacterial cell wall synthesis. Vancomycin is a critical option for serious MRSA infections, including bloodstream infections, pneumonia, and endocarditis. Its use is generally reserved for cases where other antibiotics have failed or are inappropriate due to resistance concerns.

Sales Channel: Expanding preference towards online channels due to easy access

Patients diagnosed with or suspected of having MRSA infections often access medications directly through hospital pharmacies. This channel is preferred due to the immediate need for administering drugs in potentially life-threatening situations. Hospitals stock these critical care antibiotics to ensure quick availability. In addition, for outpatients or those managing chronic MRSA infections, retail pharmacies serve as a primary source for obtaining prescribed MRSA drugs. They offer convenience for patients and caregivers.

Online channels offer unmatched convenience, allowing for easy reordering and home delivery. This is particularly advantageous for patients with mobility issues or those residing in remote areas. Some manufacturers have started offering MRSA drugs directly through their websites. This channel particularly benefits patients with long-term prescriptions, offering convenience and potentially lower costs. Moreover, with the rise of e-commerce, online pharmacies have become a viable channel. They cater to tech-savvy consumers looking for easy access, comparison shopping, and home delivery options.

Regional Insights

The Americas region represents a significant market for MRSA drugs, driven by advanced healthcare infrastructure and high awareness of MRSA infections. The consumer needs in these regions focus on effective, fast-acting antibiotics and treatments with minimal side effects. Customers in North America prefer drugs with proven efficacy, backed by robust clinical trials. There has been a notable investment in research for developing novel antibiotics and therapies, including initiatives by the government and private sectors to combat antibiotic resistance. Recent patents in the US and Canada reflect ongoing innovation in MRSA treatment options, emphasizing safer and more effective antibacterial agents. The European Union (EU) countries have a diverse market for MRSA drugs, strongly emphasizing public health initiatives and antibiotic stewardship programs to manage MRSA outbreaks. The need for MRSA drugs is geared towards treatments compatible with these stewardship programs, highlighting a preference for novel mechanisms of action and lower resistance profiles. Investment in EU countries is robust, with public and private sectors funding research into new antibiotics. The Middle East and Africa show varying levels of market development for MRSA drugs, with the Middle East having more advanced healthcare systems in countries like the UAE and Saudi Arabia. Both regions have a growing demand for effective MRSA treatments due to increasing antibiotic resistance. Efforts in these regions include improving healthcare infrastructure, public awareness campaigns, and investments in research to tailor treatments to the genetic profiles of local MRSA strains. China, Japan, and India represent key Asian Pacific markets, each with distinct consumer needs and purchasing behaviors. In China and India, the rapid increase in MRSA infections has underscored the need for affordable and accessible treatment options. Both countries are focusing on bolstering their antibiotic research and development capabilities, with China investing heavily in new drug development and India enhancing its generic drug production to include MRSA antibiotics.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Methicillin-Resistant Staphylococcus Aureus Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Methicillin-Resistant Staphylococcus Aureus Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Methicillin-Resistant Staphylococcus Aureus Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Aridis Pharmaceuticals Inc., Armata Pharmaceuticals, Inc., AstraZeneca PLC, Basilea Pharmaceutica Ltd., Bausch Health Companies Inc., Baxter International Inc., Becton, Dickinson and Company, Cardinal Health, Inc., Cumberland Pharmaceuticals Inc., Debiopharm SA, Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., Fresenius Kabi AG, GlaxoSmithKline PLC, Innovation Pharmaceuticals Inc., Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Nabriva Therapeutics GMBH, Novartis AG, Paratek Pharmaceuticals, Inc., Pfizer Inc., R-Biopharm AG, Shionogi Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries ltd, and Theravance Biopharma, Inc..

Market Segmentation & Coverage

This research report categorizes the Methicillin-Resistant Staphylococcus Aureus Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Agent Type
    • Ceftaroline
    • Daptomycin
    • Linezolid
    • Telavancin
    • Vancomycin
  • Route of Administration
    • Oral
    • Parenteral
  • Sales Channel
    • Offline
      • Hospitals Pharmacies
      • Retail Pharmacies
    • Online
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Methicillin-Resistant Staphylococcus Aureus Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Methicillin-Resistant Staphylococcus Aureus Drugs Market?

3. What are the technology trends and regulatory frameworks in the Methicillin-Resistant Staphylococcus Aureus Drugs Market?

4. What is the market share of the leading vendors in the Methicillin-Resistant Staphylococcus Aureus Drugs Market?

5. Which modes and strategic moves are suitable for entering the Methicillin-Resistant Staphylococcus Aureus Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of infections associated with methicillin-resistant staphylococcus aureus
      • 5.1.1.2. Rising investment in healthcare sector by private & public sector
    • 5.1.2. Restraints
      • 5.1.2.1. Fluctuating cost of raw materials used in methicillin-resistant staphylococcus aureus drugs formulations
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research & development activities to develop novel methicillin-resistant staphylococcus aureus drugs
      • 5.1.3.2. Increasing number of patent expiration of methicillin-resistant staphylococcus aureus drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Time consuming and strict regulatory approval processes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Agent Type: Evolving adoption of daptomycin for effective treatment of MRSA
    • 5.2.2. Sales Channel: Expanding preference towards online channels due to easy access
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Agent Type

  • 6.1. Introduction
  • 6.2. Ceftaroline
  • 6.3. Daptomycin
  • 6.4. Linezolid
  • 6.5. Telavancin
  • 6.6. Vancomycin

7. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral

8. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Sales Channel

  • 8.1. Introduction
  • 8.2. Offline
  • 8.3. Online

9. Americas Methicillin-Resistant Staphylococcus Aureus Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. UK Government's Strategic Investment in Global AMR Surveillance, Strengthening Health Systems Across Asia and Africa
    • 12.3.2. Basilea Seeks FDA Approval for New MRSA-Fighting Antibiotic Ceftobiprole
    • 12.3.3. BARDA's Strategic Funding Initiative for Melinta Therapeutics to Enhance Pediatric Antibiotic Access
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET DYNAMICS
  • FIGURE 7. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEFTAROLINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEFTAROLINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LINEZOLID, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LINEZOLID, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TELAVANCIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TELAVANCIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY VANCOMYCIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY VANCOMYCIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 47. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 48. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 49. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 50. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 55. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 58. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 59. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 60. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 63. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 64. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 65. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 66. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 67. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 68. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 71. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 74. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 79. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 82. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 100. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 102. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 104. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 107. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 110. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 111. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 112. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 115. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 118. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 119. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 120. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 123. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 126. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 127. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 128. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 131. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 134. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 135. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 136. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 139. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 142. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 143. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 144. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 150. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 152. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 155. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 158. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 159. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 160. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 166. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 171. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 174. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 175. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 176. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 179. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 182. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 183. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 184. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 187. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 190. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 191. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 192. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 205. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 208. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 209. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 210. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 213. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 216. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 217. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 218. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 221. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 224. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 225. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 226. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 229. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 232. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 233. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 234. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 237. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 240. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 241. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 242. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 245. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 248. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 249. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 250. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 253. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 256. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 257. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 258. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AGENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS METHICILL